Arcturus Therapeutics Holdings Inc. Stock News

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public R

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $1.69. This compares to earnings of $4.33 per share a year ago.

Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.

While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.

Biotech stocks are often at the forefront of innovation. These are the companies we hear about that are driving breakthroughs in healthcare.

We've all heard the story with AI by now, and for good reason. It has massive potential to overhaul almost every aspect of our lives.

Arcturus Therapeutics is a biotechnology company specializing in rare and infectious diseases, with approved COVID and influenza vaccines in Japan and the EU. The company is developing game-changing t

Arcturus Therapeutics Holdings Inc. interim results from the phase 1b study, using ARCT-032 for the treatment of patients with Cystic Fibrosis, are expected in the 1st half of 2024. The global Cystic

With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the digital

With such a high demand for items that can improve our longevity and health, biotechnology is at the forefront of today's innovation. Biotech products allow us to better understand the human body and

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company

Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.

Arcturus Therapeutics is a biotech firm focused on mRNA vaccine development and delivery technologies. The company's core investment thesis is centered around its cutting-edge research and its ability

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2023 Earnings Call Transcript

These companies in the biotechnology sector are doing incredible work and achieving wonderful developments. The result is not not only growth and profit for the companies, but they are also offering e